市場調查報告書
商品編碼
1308699
到 2030 年智能吸入器市場預測 - 按產品、按適應症(哮喘、慢性阻塞性肺疾病)、按分銷渠道、按最終用戶、按地區進行全球分析Smart Inhalers Market Forecasts to 2030 - Global Analysis By Product, Indication (Asthma and Chronic Obstructive Pulmonary Disease ), Distribution Channel, End User and By Geography |
智能吸入器是通過藍牙與移動應用程序配對的小工具,可有效管理慢性呼吸道疾病並改善患者的生活方式。 此外,根據用戶過去的用藥歷史,這些智能設備可以發送提醒和警報。 哮喘、囊性纖維化和慢性阻塞性肺病等呼吸系統疾病正變得司空見慣,對智能吸入器的需求猛增。
根據世界衛生組織 2021 年報告,哮喘是一種主要的非傳染性疾病 (NCD),影響兒童和成人,2019 年估計有 2.62 億人受到影響。2019 年有 461,000 人死亡。
由於空氣污染和吸煙習慣的增加,哮喘和慢性阻塞性肺病變得越來越普遍,推動了市場對智能吸入器的需求。 ODPHP 疾病預防和健康促進辦公室估計,2020 年全球將有超過 3.39 億哮喘病例,其中 2500 萬是美國人,1480 萬將被診斷患有慢性阻塞性肺病。 哮喘是兒童和老年人最常見的疾病。 這種非傳染性疾病正在通過吸煙習慣的增加和全球空氣污染水平的上升而傳播。
由於智能吸入器的無線連接和記錄患者數據的能力,數據洩露和濫用的風險顯著增加。 此外,由於患者和醫生的接受度很低,預計智能吸入器將阻礙市場擴張。
在預測期內,醫療設備和藥物輸送設備中數字技術的日益採用預計將加速市場增長。 除此之外,哮喘和慢性阻塞性肺病等呼吸系統疾病的患病率不斷上升,預計將為增加數字吸入器的採用提供重要機會。 例如,美國疾病控制與預防中心 (CDC) 的一項研究估計,2016 年美國有 2650 萬哮喘患者。 上述因素可能會極大地刺激這些智能吸入器的市場擴張。
儘管智能吸入器的好處越來越大,但手動吸入器作為替代產品的存在可能會在一定程度上限制市場的擴張。 阻礙智能吸入器市場擴張的另一個關鍵因素是新興經濟體民眾對數字吸入器的使用缺乏認識。
COVID-19 的全球爆發預計將為智能吸入器領域的市場進入者帶來利潤豐厚的增長機會。 此次疫情對市場產生了積極影響,因為 COPD 和哮喘患者因 COVID-19 而面臨更高的住院風險。 因此,在此期間,COVID-19 患者數量的不斷增加和呼吸系統疾病的負擔增加了智能吸入器的需求和採用。
預計在預測期內,醫院藥房部門將佔據最大的市場份額。 在醫院接受治療的患者可以輕鬆前往醫院藥房。 此外,許多給藥系統製造商與醫院藥房有銷售協議。 因此,在預測期內,上述因素強烈表明銷售智能吸入器的醫院藥房市場將遵循積極的增長軌跡。
由於全球慢性阻塞性肺病患者數量不斷增加,預計未來幾年市場增長將帶來豐厚回報。 例如,世界衛生組織 (WHO) 估計,慢性阻塞性肺病是 2019 年全球第三大死亡原因,奪去了超過 323 萬人的生命。 此外,許多風險因素,包括長期吸煙、室內空氣污染、有害氣體和顆粒物以及職業粉塵,都會影響慢性阻塞性肺病的患病率,需要持續的護理管理。 因此,慢性阻塞性肺病患病率的上升和對有效治療的需求不斷增長將在預測期內推動該細分市場的需求。
由於該地區國家主要市場參與者的活動增加,預計北美地區市場在預測期內將佔據全球智能貨架市場的最高份額。 北美智能貨架市場包括引入和部署採用先進技術的智能貨架系統,以在零售環境中提供增強的購物體驗、改進的庫存管理和實時數據分析。 北美零售商越來越多地採用自動化和數字化來簡化運營並提高客戶參與度。 智能貨架可實現實時庫存跟蹤,因此零售商可以優化庫存水平、減少缺貨並提高整體庫存管理效率。
由於人口老齡化嚴重、可支配收入增加、醫療保健成本上升以及一系列發展舉措,亞太地區預計將經歷快速增長。 新興經濟體不斷增加的醫療保健 IT 開發支出也促進了該地區的增長。 此外,印度和中國的亞太智能吸入器市場預計將快速增長。
2023 年 6 月,H&T Presspart 計劃進一步投資 L'Arboc。 全球供應的萬託林定量吸入器執行器是在塔拉戈納的 L'Arboc (Baix Penedes) 製造的。 H&T Presspart 年產注塑塑料給藥部件和裝置合計超過 10 億件,過去兩年在 Larboc 工廠投資超過 2000 萬歐元,將產能擴大到 3,000 平方米的潔淨廠房我們擴大了生產設施。
2023 年2 月,Teva Pharmaceutical Industries Ltd. 的美國子公司Teva Pharmaceuticals USA, Inc. 宣布將參加2 月24 日至27 日在德克薩斯州聖安東尼奧舉行的美國過敏、哮喘和免疫學大會。 (AAAAI) 宣布將在 2023 年年會上展示有關 Digihaler 系統的新數據。 這些數據包括 CONNECT2 臨床試驗計劃的結果,以及患者和醫療保健專業人員在現實世界中使用智能吸入器系統的信息。 Digihaler 系統是第一個也是唯一一個帶有內置傳感器的智能吸入器系統,可提供客觀的吸入事件數據,幫助患者和醫生支持哮喘管理並製定個性化的治療計劃。
2022年12月,澳大利亞醫用大麻公司ECS Botanics宣布將為藥用乾花供應蒸發器裝置。 該公司表示,已簽署一項協議,從一家未具名的公司進口和供應智能計量吸入器及相關軟件。
According to Stratistics MRC, the Global Smart Inhalers Market is accounted for $1.42 billion in 2023 and is expected to reach $2.60 billion by 2030 growing at a CAGR of 9% during the forecast period. Smart inhalers are gadgets made to pair with a mobile app via Bluetooth in order to manage chronic respiratory conditions effectively and enhance patients lifestyles. Additionally, based on a user's past history of dosage administration, these smart devices are able to send reminders and alerts to them. Asthma, cystic fibrosis, and chronic obstructive pulmonary disorders, among other respiratory illnesses, are becoming more common, which has caused an exponential rise in the demand for smart inhalers.
According to the WHO 2021 report, asthma is a major noncommunicable disease (NCD), affecting both children and adults, and has affected an estimated 262 million people in 2019 and caused 461000 deaths in the same year.
Asthma and COPD are becoming more common due to an increase in air pollution and smoking habits, which is driving market demand for smart inhalers. The ODPHP Office of Disease Prevention and Health Promotion estimates that there will be over 339 million asthma patients worldwide in 2020, of whom 25 million are Americans with a COPD diagnosis of 14.8 million. Asthma is the most prevalent disease among children and the elderly. This non-communicable disease is spreading due to an increase in smoking habits and rising levels of global air pollution.
The risk of data leakage and misuse has increased significantly as a result of smart inhalers' wireless connectivity and ability to record the patient's data. Additionally, the smart inhaler has a very low level of patient and physician acceptance, which is anticipated to impede market expansion.
During the forecast period, it is anticipated that rising digital technology adoption in medical devices and the effectiveness of drug delivery devices in therapeutic measures will accelerate market growth. In addition to this, it is predicted that an increase in the prevalence of respiratory conditions like asthma and COPD will present a significant opportunity for the increased adoption of digital inhalers. For instance, a study by the Centers for Disease Control and Prevention (CDC) estimated that in 2016, there were 26.5 million asthma sufferers in the United States. The aforementioned factors will significantly fuel the market expansion of these smart inhalers.
Despite the growing benefits of smart inhalers, the availability of manual inhalers as a substitute product may limit market expansion to some extent. Another significant factor impeding the market expansion of smart inhalers is the lack of awareness regarding the use of digital inhalers among the populace of developing economies.
The global COVID-19 outbreak is anticipated to present lucrative growth opportunities for market participants in the smart inhaler space. Due to the high risk of hospitalization from COVID-19 for patients with COPD and asthma, the pandemic had a positive effect on the market. Thus, the demand for or adoption of smart inhalers is rising at this time due to rising COVID-19 cases and the burden of respiratory disorders.
In the forecasted time frame, it is predicted that the hospital pharmacies segment will account for the largest market share. The patient population receiving treatments in hospital settings has easy access to hospital pharmacies. Additionally, a number of manufacturers of smart drug delivery systems have distribution agreements with these hospital pharmacies. Therefore, during the projection period, the aforementioned factors strongly suggest a positive growth trajectory for the market for hospital pharmacies that sell smart inhalers.
Due to expanding COPD patient populations worldwide, the market growth is anticipated to witness lucrative growth in the coming years. For instance, the World Health Organization estimates that the third leading cause of death worldwide in 2019 was COPD, which claimed the lives of over 3.23 million people. Furthermore, a number of risk factors, including prolonged tobacco use, indoor air pollution, harmful gases and particles, and occupational dust, influence the prevalence of COPD and necessitate ongoing care management. As a result, segmental demand will be driven over the anticipated period by the rising prevalence rate of COPD and the rising need for effective treatment.
The North America region market is estimated to witness the highest share of the global Smart Shelves market during the forecast period, which is attributed to increasing activities by key market players in countries in this region. The smart shelves market in North America involves the adoption and deployment of intelligent shelving systems that incorporate advanced technologies to enhance the shopping experience, improve inventory management, and provide real-time data analytics in retail environments. Retailers in North America are increasingly embracing automation and digitalization to streamline their operations and enhance customer engagement. Smart shelves offer real-time inventory tracking, enabling retailers to optimize stock levels, reduce out-of-stock situations, and improve overall inventory management efficiency.
Due to its large elderly population, rising disposable incomes, rising healthcare costs, and numerous developmental initiatives, the Asia-Pacific region is expected to experience rapid growth. Regional growth will be aided by emerging economies' rising healthcare IT development expenditures. In addition, the markets for smart inhalers in Asia-Pacific are predicted to grow rapidly in India and China.
Some of the key players profiled in the Smart Inhalers Market include H&T Presspart Manufacturing Ltd., 3M Health Care Limited, Adherium Limited, AireHealth, Inc., Amiko Digital Health Limited, AstraZeneca, Inc., Boehringer Ingelheim GmbH, Cognita Labs, LLC, Cohero Health LLC, FindAir Sp. z o.o, GlaxoSmithKline plc, Novartis AG, OPKO Health Inc, Personal Air Quality Systems Private Limited, Philip Morris International Inc. (Vectura Group Plc), Pneuma Respiratory, Inc., Propeller Health and Teva Pharmaceuticals Industries Ltd.
In June 2023, H&T Presspart plans more investment in L'Arboc. The global supply of Ventolin metered-dose inhaler actuators are manufactured in in L'Arboc (Baix Penedes), Tarragona. With a combined annual production of more than 1,000 million units of injection-moulded plastic drug delivery components and devices, H&T Presspart has invested more than 20 million euros in its factory in L'Arboc in the last two years to expand its production capacity up to 3,000 square meters of cleanroom production facilities, with which to carry out new projects as they anticipate strong growth in the coming years.
In February 2023, Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that new data on its Digihaler System will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting, being held February 24-27 in San Antonio, Texas. The data includes findings from the CONNECT2 clinical trial program as well as information on patients and healthcare professionals' real-world use of the smart inhaler system. The Digihaler System is the first and only smart inhaler system with built-in sensors that provide objective inhaler event data to help patients and their doctors support asthma management and develop personalized treatment plans.
In December 2022, Australian medical cannabis company ECS Botanics has announced it will be supplying a vaporiser device for use with medicinal dried flower. The company says it has signed an agreement to import and supply a Smart Inhaler and associated software from an as yet un-named company that will provide metered-dose administration.